BOULDER, Colo. --(BUSINESS WIRE)--Jul. 27, 2021-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the second quarter ended June 30, 2021 after the close of trading on Tuesday,

Biodesix and Seer to discuss combined efforts to utilize Seer Proteograph™ Product Suite to drive novel proteomic insights for translational research BOULDER, Colo. --(BUSINESS WIRE)--Jun. 17, 2021-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company, today announced

Detection of circulating neutralizing antibodies produced in response to COVID-19 vaccination and infection may benefit immunocompromised individuals. BOULDER, Colo. --(BUSINESS WIRE)--Jun. 15, 2021-- Biodesix, Inc.   (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus

Biodesix intends to make its databank and linked data accessible to research and biopharma partners BOULDER, Colo. & SAN FRANCISCO --(BUSINESS WIRE)--Jun. 4, 2021-- Biodesix, Inc.  (Nasdaq: BDSX),   a leading lung cancer diagnostic solutions company, announced a strategic partnership with Datavant,

Study will evaluate the use of a blood-based biomarker to predict outcomes in high PD-L1 expressing non-small cell lung cancer patients treated with immune checkpoint inhibitors plus or minus chemotherapy   SAN CARLOS, Calif. and BOULDER, Colo. , May 26, 2021 /PRNewswire/ -- Biodesix, Inc.

BOULDER, Colo. --(BUSINESS WIRE)--May 25, 2021-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton , Chief Executive Officer of Biodesix , will present at the William Blair 41st Annual Growth Stock Conference

First Quarter 2021 Record Revenue of Approximately $28.9 Million Representing 466% Growth over First Quarter 2020 Announced Plans to Launch Two New Diagnostic Tests - SARS-CoV-2 Neutralization Antibody Detection Test and Next Generation Sequencing Test BOULDER, Colo.

Blood-based NGS Test is Shown in Recent Publication to Provide Critical Data in 72 Hours; Launch Planned for First Half of 2022 BOULDER, Colo. --(BUSINESS WIRE)--Apr. 28, 2021-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, has

Dr. Laura Peek and Dr. Sean Taylor presenting novel data on SARS-CoV-2 Neutralizing Antibody Testing; Commercial Launch Planned for Summer 2021 BOULDER, Colo. --(BUSINESS WIRE)--Apr. 26, 2021-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung

BOULDER, Colo. --(BUSINESS WIRE)--Apr. 26, 2021-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the first quarter ended March 31, 2021 after the close of trading on Tuesday,